News | January 06, 2012

Bard Acquires Drug-Eluting Balloon Maker Lutonix

January 6, 2012 - C. R. Bard recently announced it acquired drug-eluting balloon maker Lutonix Inc. for $225 million. Following successful approval of a U.S. Food and Drug Administration (FDA) pre-market approval (PMA), an additional $100 million will be paid.

The transaction is structured as a merger. Lutonix, located in Minneapolis, Minn., is conducting the first and only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease. Drug-coated balloons have received growing attention in recent years as physicians look for effective ways to treat diseased arteries without having to leave a permanent implant behind. Independent forecasts suggest that the global peripheral vascular market for drug-coated balloons could approach $1 billion annually over the next decade. To date, no such device is approved for use in the United States.

The Lutonix LEVANT 2 study is a prospective, randomized, single-blinded, multi-center pivotal IDE trial comparing the Lutonix drug-coated balloon to standard balloon angioplasty. The trial will enroll 476 patients across 55 sites, including 40 in the United States and 15 in Europe. Lutonix began recruiting patients in the third quarter of 2011 and has enrolled over 160 patients to date. Eligible patients suffer from significant stenosis in previously unstented superficial femoral artery or popliteal artery lesions up to 150 mm in length. These patients will be followed for five years, with PMA submission after one year of follow-up. At this time, the company anticipates that submission could occur in 2014.

Lutonix received CE mark approval this year and Bard expects to start selling the device in Europe in the second half of 2012. The company plans to begin a larger registry study concurrent with the European launch to support broader marketing claims and obtain additional clinical data.

Timothy M. Ring, Bard’s chairman and CEO, commented, “In our evaluations, Lutonix has the only third-generation drug-coated balloon technology. They also have a significant lead with respect to U.S. launch, outstanding quality and depth of pre-clinical science, a strong clinical program, a very skilled and motivated team, and a coating technology we believe will demonstrate superior safety and efficacy. This position of leadership in a large potential market, combined with our current market leadership in PTA, makes this acquisition a compelling strategic fit for Bard.”

Bard expects this transaction to reduce 2012 earnings per share by approximately 25 cents, excluding items that affect comparability.

For more information:

Related Content

Orchestra BioMed Partnering With Terumo Corp. for Development, Commercialization of Virtue Sirolimus-eluting Balloon
News | Drug-Eluting Balloons | June 13, 2019
Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for development and...
Philips Shares Three-Year Results for Stellarex .035 Drug-Coated Balloon
News | Drug-Eluting Balloons | May 29, 2019
Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomized...
Concept Medical Inc. Granted Breakthrough Device Designation for MagicTouch Sirolimus Coated Balloon
News | Drug-Eluting Balloons | May 02, 2019
Concept Medical Inc. (CMI) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration...
Orchestra BioMed Receives FDA Breakthrough Device Designation for Virtue Sirolimus-eluting Balloon
Technology | Drug-Eluting Balloons | April 24, 2019
Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for...
News | Drug-Eluting Balloons | March 06, 2019
Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and Drug...
Philips Releases Three-Year Data on Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | January 28, 2019
Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated with Philips’...
Virtue Sirolimus-Eluting Balloon Demonstrates Positive Safety and Efficacy at Three Years
News | Drug-Eluting Balloons | September 25, 2018
Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent...
Three-Year Real-World Data Support In.Pact Admiral as Primary PAD Therapy
News | Drug-Eluting Balloons | September 24, 2018
 New data announced at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego,...
FDA Approves 200, 250 Millimeter In.Pact Admiral Drug Coated Balloons
Technology | Drug-Eluting Balloons | June 15, 2018
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for 200mm and 250mm lengths of the In.Pact...
News | Drug-Eluting Balloons | May 29, 2018
M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus micro-reservoir drug-...
Overlay Init